Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Canopy Growth Corp T.WEED

Alternate Symbol(s):  CGC | T.WEED.DB

Canopy Growth Corporation is a cannabis company. It delivers innovative products with a focus on premium and mainstream cannabis brands, including Doja, 7ACRES, Tweed, and Deep Space, in addition to category-defining vaporizer technology made in Germany by Storz & Bickel. The principal activities of the Company are the production, distribution and sale of a diverse range of cannabis and cannabinoid-based products for both adult-use and medical purposes under a portfolio of distinct brands in Canada. Its Canada cannabis segment includes the production, distribution, and sale of a range of cannabis, hemp, and cannabis related products in Canada. International markets cannabis segment includes the production, distribution, and sale of a range of cannabis and hemp products internationally. Storz & Bickel segment includes the production, distribution, and sale of vaporizers. This Works segment includes the production, distribution and sale of beauty, skincare, wellness and sleep products.


TSX:WEED - Post by User

Bullboard Posts
Comment by Bobthebuilddron Jan 08, 2017 12:34pm
72 Views
Post# 25680503

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:Just some food for thought

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:Just some food for thought From googling Mettrum Q2 2017. Revenues increased 180% to 4,790,022, vs the same reporting period of Q2 in 2016.Gross profit increased 67%. Registered clients increased 253% to 15330. A current cash position of 24 million. As a note. This as of November 15, 2016. So it's obviously out of date. And is compared to Q2 reporting period in 2016. There Q3 reporting period should be coming soon and will give a better view. Canopy Q2 2017. This is as of Nov 2016. Also out of date. But that was there last reporting period. Revenue 8.5 million which is a increase of 22% over Q1. Over 24,400 patients as of September 30th 2016. 45.4 million in cash and cash equivalent plus the additional 60 million for a private placement. So as a highlight once the merger in complete on January 27th, 2016. Combined quarterly revenue of $13,290,000 (assuming everything stays the same) or $53,160,000 annually. 39730 clients nationwide. Assuming zero growth which is impossible.
YodaLayhehoo wrote:
Where are you getting this data from the last quarter I saw good patient counts was when they were at 11,000 patients and added to 16,000. The quarter saw 7 million in revenue. They added 1333 patients per month. Revenue per month 2.33 million. So the average $per month is $212, $189, $170 which is $580 I stopped researching this number so you could be right. I know the last time a daw a patient count it was 25,000 for Canopy. Is it somewhere on the new financials thanks


Bullboard Posts